Publication: Treating chronic hepatitis delta: the need for surrogate markers of treatment efficacy
Files
Program
KU-Authors
KU Authors
Co-Authors
Abbas, Zaigham
Buti, Maria
Cornberg, Markus
Esteban, Rafael
Etzion, Ohad
Ganes, Edward J.
Gish, Robert G.
Glenn, Jeffrey S.
Hamids, Saeed
Heller, Theo
Editor & Affiliation
Compiler & Affiliation
Translator
Other Contributor
Date
Language
Type
Embargo Status
NO
Journal Title
Journal ISSN
Volume Title
Alternative Title
Abstract
Chronic hepatitis delta represents the most severe form of chronic viral hepatitis. The current treatment of hepatitis delta virus (HDV) infection consists of the use of interferons and is largely unsatisfactory. Several new compounds are currently in development for the treatment of HDV infection. However, surrogate markers that can be used to develop clinical endpoints in HDV infection are not well defined. In the current manuscript, we aimed to evaluate the existing data on treatment of HDV infection and to suggest treatment goals (possible "trial endpoints") that could be used across different clinical trials.
Source
Publisher
Elsevier
Subject
Medicine, Gastroenterology and hepatology
Citation
Has Part
Source
Journal of Hepatology
Book Series Title
Edition
DOI
10.1016/j.jhep.2018.12.022